Levin A, Stevens P, Bilous B, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; (Suppl.)1-150.
GBD 2015 DALYs and HALE Collaborators, 2016. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2015; 388(10053): 1603-58.
GBD 2016 Causes of Death Collaborators, 2017. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study. Lancet 2016; 390: 1151-210.
Jaffe M. A new reaction of creatinine in normal generated urine with picric acid and its precipitation products. Physiologische Chemie 1886; 10: 391-400.
Folin O, Morris J. On the determination of creatinine and creatine in urine. J Biol Chem 1914; 17: 469-73.
Hsiung SK, Chou JC, Sun TP, et al. Dual type potentiometric biosensor US Patent No7758733 B2. 2010.
Ozin GA, Arsenault AC, Cademartiri L. Nanochemistry: a chemical approach to nanomaterials. 2nd ed. Royal Society of Chemistry 2009.
Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-28.
Kidney disease: improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 113(Suppl.): s1-s130.
Fernandez F, Hill MJ. Proceedings: the production of vitamin k by human intestinal bacteria. J Med Microbiol 1975; 8(2)
Schloerb PR. Intestinal dialysis for kidney failure. Personal experience. ASAIO Trans 1990; 36(1): 4-7.
Marier JF, Guilbaud R, Kambhampati SRP, et al. The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. J Clin Pharmacol 2006; 46: 310-20.
Niwa T, Nomura T, Sugiyama S, et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulphate levels in undialyzed uremic patients. Kidney Int 1997; 52(Suppl.): s23-8.
Owada K, Nakao M, Koike J, et al. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int 1997; 63: 188-90.
de Smet R, Thermote F, Lameire N, et al. Sevelamer hydrochloride (Renagel) absorbs the uremic compounds indoxyl sulphate, indole and p-cresol. J Am Soc Nephrol 2004; 15(Abstract) a505.